AFN 1252,
AFN-1252,
AFN1252,
API 1252,
API-1252,
API1252,
AFN-1252,
API-1252,
UNII-T3O718IKKM,
620175-39-5,
T3O718IKKM,
CHEMBL1652621,
QXTWSUQCXCWEHF-JXMROGBWSA-N,
API 1252,
Debio 1452,
SCHEMBL724936,
SCHEMBL724937,
DTXSID10211069,
AFN-1252(Debio 1452),
AFK-1252,
AFN 1252,
BCP19135,
BDBM50052244,
ZINC38795123,
DB12658,
SB16787,
NCGC00485479-01,
2-Propenamide, N-methyl-N-((3-methyl-2-benzofuranyl)methyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)-,
AFN-12520000,
HY-16911,
(E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide,
Antibacterials, Affinium,
D00HYK,
Galapagos program, Affinium,
Antibacterials, Affinium/GSK,
Antibacterial therapeutics, Affinium,
API-1401,
CS-4313,
AFN-1252 (oral, bacterial infection),
CID10407120,
Antibacterial therapeutics, Affinium/GSK,
CID 10407120,
FabI inhibitors (antibacterial), Affinium,
AFN-1252 (oral, bacterial infection), Affinium,
Bacterial fatty acid biosynthesis inhibitors, Affinium,
(E)-3-(1,2,3,4-tetrahydro-2-oxo-1,8-naphthyridin-6-yl)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)acrylamide,